94863-06-6

Upstream product

• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 24115-89-7 3-benzyloxy-2-nitrobenzoic acid 
• 177478-27-2 2-amino-3-hydroxy-N-methylaniline 
• 177477-80-4 2-Ethyl-4-hydroxy-1-methyl-1H-benzimidazole 
• 177477-78-0 1-ethyl-4-hydroxy-2-methyl-1H-benzimidazole 
• 177478-32-9 4-hydroxy-1-methyl-2-methylamino-1H-benzimidazole 
• 177477-89-3 4-hydroxy-2-methoxy-1-methyl-1H-benzimidazole 
• 177478-24-9 4-Hydroxy-2-methoxymethyl-1-methyl-1H-benzimidazole 
• 177478-23-8 2-Ethoxy-4-hydroxy-1-methyl-1H-benzimidazole 
• 177478-25-0 2-Acetyl-4-hydroxy-1-methyl-1H-benzimidazole 
• 177477-79-1 1-Methyl-4-hydroxy-2-phenyl-1H-benzimidazole 
• 177477-87-1 2-amino-3-benzyloxy-N-methylaniline 
• 177477-74-6 4-benzyloxy-1-ethyl-2-methyl-1H-benzimidazole 
• 177477-68-8 3-benzyloxy-N-methyl-2-nitroaniline 
• 177477-76-8 4-Benzyloxy-2-ethyl-1-methyl-1H-benzimidazole 

Relevant academic research and scientific papers

Diazepane derivatives or salts thereof

To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan deriva

SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF

There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4'-bromo-2'-[(5-chloro-2-pyridyl)carbamoyl)-6-β-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2'-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4'-bromo-6'-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof.

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]